medigraphic.com
SPANISH

Acta Médica Grupo Angeles

Órgano Oficial del Hospital Angeles Health System
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
    • Send manuscript
    • Names and affiliations of the Editorial Board
  • Policies
  • About us
    • Data sharing policy
    • Stated aims and scope
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2024, Number 5

<< Back Next >>

Acta Med 2024; 22 (5)

Primary gliosarcoma, a rare variant of wild-type isocitrate dehydrogenase glioblastoma

Hernández JR, Mora CJ, Hasslacher AJF, Aguirre TJ
Full text How to cite this article 10.35366/118827

DOI

DOI: 10.35366/118827
URL: https://dx.doi.org/10.35366/118827

Language: Spanish
References: 5
Page: 424-426
PDF size: 301.81 Kb.


Key words:

gliosarcoma, primary gliosarcoma, glioblastoma, magnetic resonance imaging.

ABSTRACT

Introduction: gliosarcoma is a rare variant of glioblastoma with glial and mesenchymal components. It presents nonspecific symptoms and imaging findings, necessitating diagnosis through histopathological examination. Clinical case: a 57-year-old male with a one-month history of persistent headaches without cognitive function deficits. Magnetic resonance imaging reveals a lesion in the right temporal lobe. Surgical management confirms gliosarcoma grade 4 through histopathological examination. Conclusion: due to its rarity, gliosarcoma should be considered in the differential diagnosis of brain tumors. Despite treatment, its prognosis is unfavorable, emphasizing the need to document clinical, radiological, and immunohistochemical findings to enhance future patient care.


REFERENCES

  1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021; 23 (8): 1231-1251.

  2. García-Lezama M, Carrillo-Ruíz JD, Moreno-Jiménez S, Roldán-Valadez E. WHO CNS5 2021 incluye mutaciones específicas en gliomas que pueden ser identificadas con biomarcadores cuantitativos de resonancia magnética. Gac Méd Méx. 2023; 159 (2): 164-171.

  3. Mirchia K, Mahoney MT, Christie O, Fuller CE, Mirchia K. A rare tumor in a rare location: radiology and pathology findings with a literature review on intraventricular gliosarcoma. Cureus. 2023; 15 (2): e34622.

  4. Tuan HX, Hung ND, Minh ND, Van Anh NT, Vi NH, Duy NQ, et al. Primary intraventricular gliosarcoma on MRI: a challenging diagnosis. Radiology Case Rep. 2022; 17 (3): 685-689.

  5. Amer A, Khose S, Alhasan H, Pokhylevych H, Fuller GN, Chasen N, et al. Clinical and survival characteristics of primary and secondary gliosarcoma patients. Clin Neurol Neurosurg. 2022; 214: 107146.




Figure 1
Figure 2
Figure 3

2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Acta Med. 2024;22